{"organizations": [], "uuid": "966edeb1df2e193935728cfc7ced364ee3dbd6ee", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-acelrx-resubmits-new-drug-applicat/brief-acelrx-resubmits-new-drug-application-for-dsuvia-idUSFWN1SG0QY", "country": "US", "domain_rank": 408, "title": "BRIEF-Acelrx Resubmits New Drug Application For Dsuvia", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-09T14:20:00.000+03:00", "replies_count": 0, "uuid": "966edeb1df2e193935728cfc7ced364ee3dbd6ee"}, "author": "", "url": "https://www.reuters.com/article/brief-acelrx-resubmits-new-drug-applicat/brief-acelrx-resubmits-new-drug-application-for-dsuvia-idUSFWN1SG0QY", "ord_in_thread": 0, "title": "BRIEF-Acelrx Resubmits New Drug Application For Dsuvia", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "none"}, {"name": "acelrx pharmaceuticals inc", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9, 2018 / 11:22 AM / Updated 10 minutes ago BRIEF-Acelrx Resubmits New Drug Application For Dsuvia Reuters Staff\nMay 9 (Reuters) - AcelRx Pharmaceuticals Inc: * ACELRX RESUBMITS NEW DRUG APPLICATION FOR DSUVIA\n* ACELRX PHARMACEUTICALS INC - EXPECTS A SIX-MONTH REVIEW BY FDA WITH A PROJECTED PDUFA DATE IN Q4 2018\n* ACELRX PHARMACEUTICALS INC - ANTICIPATES THAT FDA WILL ACKNOWLEDGE ACCEPTANCE OF NDA WITHIN 30 CALENDAR DAYS OF RESUBMISSION DATE\n* ACELRX PHARMACEUTICALS INC - POTENTIAL MARKETING AUTHORIZATION FROM EMA IS EXPECTED IN Q3 OF 2018 FOR DSUVIA ", "external_links": [], "published": "2018-05-09T14:20:00.000+03:00", "crawled": "2018-05-09T14:40:43.009+03:00", "highlightTitle": ""}